RIGI and cancer: HERV-K activates innate immune responses via RIG-I and Toll-like receptor pathways, stimulates B and T cells, induces antibody and cytotoxic T-cell responses, and has potential applications in cancer immunotherapy (Yu et al., 2012; Smith et al., 2018).